跳转至内容
Merck
CN

936383

Mc-Val-Cit-PAB

≥95%

别名:

6-(2,5-Dioxo-2,5-dihydro-1H-pyrrol-1-yl)-N-((S)-1-(((S)-1-((4-(hydroxymethyl)phenyl)amino]-1-oxo-5-ureidopentan-2-yl)amino]-3-methyl-1-oxobutan-2-yl)hexanamide, N-[(1S)-1-[[(1S)-4-(carbamoylamino)-1-[[4-(hydroxymethyl)phenyl]carbamoyl]butyl]carbamoyl]-2-methylpropyl]-6-(2,5-dioxopyrrol-1-yl)hexanamide, N-[6-(2,5-Dihydro-2,5-dioxo-1H-pyrrol-1-yl)-1-oxohexyl]-L-valyl-N5-(aminocarbonyl)-N-[4-(hydroxymethyl)phenyl]-L-ornithinamide (ACI), L-Ornithinamide, N-[6-(2,5-dihydro-2,5-dioxo-1H-pyrrol-1-yl)-1-oxohexyl]-L-valyl-N5-(aminocarbonyl)-N-[4-(hydroxymethyl)phenyl]- (9CI, ACI)

登录 查看公司和协议定价

选择尺寸

关于此项目

经验公式（希尔记法）:
C28H40N6O7
分子量:
572.65
MDL编号:
MFCD26142966
UNSPSC代码:
12352209
NACRES:
NA.21

主要文件

查看所有文档
技术服务
需要帮助？我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助
技术服务
需要帮助？我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助

质量水平

100

方案

≥95%

表单

powder or crystals

颜色

white to yellow

储存温度

−20°C

SMILES字符串

[C@@H](NC([C@@H](NC(CCCCCN1C(=O)C=CC1=O)=O)[C@H](C)C)=O)(C(NC2=CC=C(CO)C=C2)=O)CCCNC(N)=O

InChI

1S/C28H40N6O7/c1-18(2)25(33-22(36)8-4-3-5-16-34-23(37)13-14-24(34)38)27(40)32-21(7-6-15-30-28(29)41)26(39)31-20-11-9-19(17-35)10-12-20/h9-14,18,21,25,35H,3-8,15-17H2,1-2H3,(H,31,39)(H,32,40)(H,33,36)(H3,29,30,41)/t21-,25-/m0/s1

InChI key

AMKBTTRWLGVRER-OFVILXPXSA-N

应用

This is a bifunctional cathepsin cleavable linker used in the construction of antibody drug conjugates (ADC).

特点和优势

The maleimide functionality can be used for bioconjugation to thiols in monoclonal antibodies while the benzyl alcohol can be used for construction of carbamate linkages with amine containing payloads.

储存分类代码

11 - Combustible Solids

WGK

WGK 3

闪点(°F)

Not applicable

闪点(°C)

Not applicable

法规信息

新产品
此项目有

历史批次信息供参考:

分析证书(COA)

Lot/Batch Number
0000368264
0000352480
0000352479
0000284562
0000352480

没有发现合适的版本？

如果您需要特殊版本，可通过批号或批次号查找具体证书。

搜索COA

已有该产品？

在文件库中查找您最近购买产品的文档。

访问文档库

Qinhuai Lai et al.
European journal of medicinal chemistry, 199, 112364-112364 (2020-05-14)
Cryptophycin-52 (CR52), a tubulin inhibitor, exhibits promising antitumor activity in vitro (picomolar level) and in mouse xenograft models. However, the narrow therapeutic window in clinical trials limits its further development. Antibody-drug conjugate (ADC), formed by coupling cytotoxic compound (payload) to an
Zixuan Ye et al.
International journal of nanomedicine, 16, 2443-2459 (2021-04-06)
Specific modifications to carriers to achieve targeted delivery of chemotherapeutics into malignant tissues are a critical point for efficient diagnosis and therapy. In this case, bovine serum albumin (BSA) was conjugated with cetuximab-valine-citrulline (vc)-doxorubicin (DOX) to target epidermal growth factor

我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系客户支持